Devices, systems and methods for inhibiting invasion and metastases of cancer
US-2017285003-A1 · Oct 5, 2017 · US
US12098352B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12098352-B2 |
| Application number | US-202016983850-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 3, 2020 |
| Priority date | Feb 5, 2018 |
| Publication date | Sep 24, 2024 |
| Grant date | Sep 24, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
An in vitro microfluidic “organ-on-chip” device is described herein that mimics the structure and at least one function of specific areas of the epithelial system in vivo. In particular, a stem cell-based Lung-on-Chip is described. This in vitro microfluidic system can be used for modeling differentiation of cells on-chip into lung cells, e.g., a lung (Lung-On-Chip), bronchial (Airway-On-Chip; small-Airway-On-Chip), alveolar sac (Alveolar-On-Chip), etc., for use in modeling disease states of derived tissue, i.e. as healthy, pre-disease and diseased tissues. Additionally, stem cells under differentiation protocols for deriving (producing) differentiated lung cells off-chips may be seeded onto microfluidic devices at any desired point during the in vitro differentiation pathway for further differentiation on-chip or placed on-chip before, during or after terminal differentiation.
Opening claim text (preview).
What is claimed is: 1. A method, comprising: a) providing a microfluidic device comprising functional Type II lung parenchyma cells and a stroma area or layer comprising fibroblast cells; and b) culturing said functional Type II lung parenchyma cells and said fibroblast cells such that said functional Type II lung parenchyma cells secrete surfactant C in amounts between 30-100 ng/ml, wherein said amounts are secreted daily from day 9 to day 15 of culture. 2. The method of claim 1 , further comprising the step of c) detecting said surfactant C at the protein level. 3. The method of claim 2 , wherein said detecting is by antibody staining. 4. The method of claim 1 , wherein said microfluidic device comprises a surface of a microfluidic channel, said microfluidic channel in fluid communication with a source of fluid. 5. The method of claim 1 , wherein said functional Type II lung parenchyma cells are exposed to an air-liquid interface. 6. The method of claim 1 , wherein said microfluidic device comprises a surface of a chamber, said chamber comprising said stroma area or layer. 7. The method of claim 6 , wherein said stroma area or layer is located adjacent to a spiral channel, wherein said stroma area or layer is separated from the spiral channel by a stretchable membrane. 8. The method of claim 7 , wherein said spiral channel comprises a confluent layer of endothelial cells. 9. A method, comprising: a) providing a microfluidic device comprising functional Type II lung parenchyma cells and a stroma area or layer, wherein each of said stroma area or layer comprises fibroblast cells; and b) culturing said functional Type II lung parenchyma cells and said fibroblast cells such that said functional Type II lung parenchyma cells secrete surfactant C in amounts between 30-100 ng/ml, wherein said surfactant C is secreted in an amounts greater than where said functional Type II lung parenchyma cells are cultured in the absence of said fibroblast cells, wherein said amounts are secreted daily from day 9 to day 15 of culture after introducing said functional Type II lung parenchyma cells into said microfluidic device. 10. The method of claim 9 , further comprising the step of c) detecting said surfactant C at the protein level. 11. The method of claim 10 , wherein said detecting is by antibody staining. 12. The method of claim 9 , wherein said microfluidic device comprises a surface of a microfluidic channel, said microfluidic channel in fluid communication with a source of fluid. 13. The method of claim 9 , wherein said functional Type II lung parenchyma cells are exposed to an air-liquid interface. 14. The method of claim 9 , wherein said microfluidic device comprises a surface of a chamber, said chamber comprising said stroma area or layer. 15. The method of claim 9 , wherein said microfluidic device comprises a stretchable membrane. 16. The method of claim 15 , wherein said stroma area or layer is located adjacent to a spiral channel, wherein said stroma area or layer is separated from the spiral channel by said stretchable membrane. 17. The method of claim 16 , wherein said spiral channel comprises a confluent layer of endothelial cells. 18. The method of claim 16 , further comprising stretching said membrane. 19. A method, comprising: a) providing: i) a microfluidic device comprising a surface and ii) a population of living cells, wherein at least a portion of said living cells have the capability to differentiate into functional Type II lung parenchyma cells; b) introducing said living cells into said microfluidic device such that said living cells are positioned on said surface of said microfluidic device so as to create positioned cells; and c) exposing said positioned cells to conditions that cause at least a portion of said positioned cells to differentiate into functional Type II lung parenchyma cells secreting surfactant C in amounts between 30-100 ng/ml, wherein said amounts are secreted daily from day 9 to day 15 of culture after introducing said living cells into said microfluidic device. 20. The method of claim 19 , further comprising the step of d) detecting said surfactant C at the protein level. 21. The method of claim 20 , wherein said detecting is by antibody staining. 22. The method of claim 19 , wherein said surface of said microfluidic device comprises a surface of a microfluidic channel, said microfluidic channel in fluid communication with a source of fluid. 23. The method of claim 19 , wherein in step c) said positioned cells are exposed to an air-liquid interface.
Pulmonary diseases · CPC title
by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip · CPC title
3D culture · CPC title
from embryonic cells · CPC title
Screening or testing on artificial tissues · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.